Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab
US Exec Ivan Cheung Expects ‘More Open Access’ To Drug
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.
